iCARE (Asthma)

iCARE (Asthma)

Es posible que algunos contenidos no estén disponibles en español.

Purpose of this Study

We are doing this study to compare the outcomes and results of two newer asthma relief therapies (called MART and PARTICS). We want to know if either option seems to be more effective for most people with moderate-to-severe asthma.

Who Can Participate?

Eligibility

Adults ages 18-75 who:
  • Have been diagnosed with asthma for at least 1 year
  • Have had at least 1 asthma attack in the past year that required oral/intravenous steroid use and/or admission to the hospital
  • Are prescribed a daily inhaled corticosteroid and/or long acting beta agonist medication
For more information, contact the study team at jessica.shier@duke.edu.

Age Range

18-75

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No

What is Involved?

Description

This study will last for about 5 years. If you choose to join the study, you will get a random assignment (like a coin flip) to follow either a MART or PARTICS medication regimen. MART: This stands for Maintenance And Reliever Therapy. If you are assigned to this group, you will use a combination ICS/LABA inhaler (Symbicort or Dulera) every day. If you start to have asthma symptoms, you will use this same inhaler as a rescue inhaler to relieve your symptoms. You will no longer use an albuterol rescue inhaler. PARTICS: This stands for Patient Activated Reliever Triggered Inhaled CorticoSteroids. If you are in this group, you will get an accessory inhaled corticosteroid inhaler to use along with your rescue inhaler if you feel symptoms. Aside from this addition, you will not have any other changes made to your routine asthma medications.

Locations

Remote/online

Compensation

Yes

Spanish Materials Available

No

Study Details

Full Title

Improving the quality of Care for Asthma patients at Risk of Exacerbations

Principal Investigator

Isaretta
Riley

Protocol Number

PRO00116584

Phase

N/A

Enrollment Status

Open to Enrollment